Looking to publish in Expert Review of Neurotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowExpert Review of Neurotherapeutics is a MEDLINE-indexed international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on the use of drugs and medicines in clinical neurology and neuropsychiatry. The journal focuses on disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines, and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's, and it does not publish case reports or case series.
Looking to publish in Expert Review of Neurotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Expert Review of Neurotherapeutics accepts the following article types. Click on an article type to view submission instructions.
Original Research
Review Article
Systematic Reviews
Meta-Analyses
Clinical Trial Report
Drug Profile
Letter To The Editor
Recent Publications
Navigating long-acting antipsychotic decision-making in schizophrenia: clinical considerations and best practices
Justin Faden, Leslie Citrome
Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome
Hannah M. Rea, Julia T. Mattson, Vardan Arutiunian, Alyssa Verdes, Suvekcha Bhattachan, Megha Santhosh, Abigail Garcia, Anika Ajwani, Meaghan Bowen, Susan Faja, Ellen Hanson, Katherine Pawlowski, Robin P. Kochel, Lisa Prock, Jeremy Veenstra-VanderWeele, Karen Walton-Bowen, Adam Vogel, Angela Morgan, Sara Jane Webb, Paul P. Wang
STS101 nasal powder as a new treatment option for acute migraine with or without aura in adults
Bradley Ong, Teshamae S. Monteith
A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions
Stephen Rush, Henry A. Nasrallah
Profiling galcanezumab in episodic migraine, cluster headache, and medication overuse headache
Abimael González-Hernández, José D. Ferrusca, Carlos M. Villalón
Frequently asked questions
How long does it take to publish?
Accepted Author Version published online in 3 days after acceptance provided the copyright form has been received. Accelerated Publication Plus offers a final decision in as little as 3 weeks from submission, with peer review in approximately 2 weeks, first proofs within 5 working days, and online publication usually 1–2 weeks after acceptance. Accelerated Publication offers a final decision in as little as 9 weeks from submission, with peer review within approximately 4 weeks, first proofs within 5 working days, and online publication usually 2–3 weeks after acceptance. Corrections to proofs should be returned within 48 hours.
Reformat to Expert Review of Neurotherapeutics using Livewrite PremiumIs a cover letter required?
A covering letter is required. Complete submissions must include a covering letter and a Disclosure Form. The letter should provide corresponding author contact details, confirm originality and exclusive submission, confirm author approval and ICMJE conditions, state ethical approval, and disclose financial relationships or declare that none exist.
Reformat to Expert Review of Neurotherapeutics using Livewrite PremiumWhat are the publication costs?
Institutional subscription pricing is USD 6,169.00 for online only and USD 9,032.00 for print and online. Personal subscription pricing is available on request.
Reformat to Expert Review of Neurotherapeutics using Livewrite Premium